Medtronic puts money on heart valve firm:
This article was originally published in Clinica
Minimally-invasive heart valve replacement technologies developer Arbor Surgical Technologies has closed a $20m series C financing round led by Medtronic. This brings the total amount of investment received by the privately held, Irvine California firm to $54m. The proceeds will be used to fund US clinical trials of Arbor's lead products, the Trilogy aortic valve system and the sutureless TRE implantation tool. The venture capital from Medtronic is part of a licensing deal, in which Minneapolis, Minnesota company acquires manufacturing, marketing and distribution rights to Arbor's trilobal perdicardial valves. Arbor will retain exclusive rights to the Trilogy and TRE technologies.
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.